BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Amendment to CLAIMS

Claim 1 (Previously Presented): Use of one or more compounds having agonist activity to a 5-HT_4 receptor in the manufacture of a medicament for therapeutic or prophylactic treatment of disorders involving human bronchocontraction, chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, wherein said compounds have the capacity of reducing pathological bronchocontraction by at least 30%, preferably at least 60%, and most preferably at least 90%, and wherein said compound is chosen from the group comprising the following 5-HT_4 receptor agonists: benzamides containing the structural element 4-amino-5-chloro-2-methoxy benzamide based on metoclopramide, with the structural formula:



having a basic nitrogen in a side chain from the amide nitrogen, said basic nitrogen often being a part of a sterically locked system, preferably BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML-1035, Mosapride, R076186, Renzapride, RS 67506, Cinitapride, SB 205149, SC-49518, SC-52491, SC-53116, SDZ 216,454, TKS 159, Y-34959, YM-09151, YM-47813, and Zacopride;

benzoic acid esters:



preferably ML 10302, RS 57639, and SR 59768;

a 2,3-dihydro-bensofuran-7-carboxamide compound, preferably ADR 932, Prucalopride (=R 093877), and SK-951;



benzofuranes and benzotiophenes,





the benzodioxan



SB 204070

the benzoic acid antagonist RS 23597 (an ester) transformed to an agonist by conversion to a ketone



e.g. preferably RS 67333 and RS 17017;
naphtalimides, preferably RS 56532;





benzindolones;

compounds in which the amide function has been replaced with an oxadiazol ring;



preferably YM-53389;

benzimidazolone-1-carboxamides



preferably BIMU 1, BIMU 8, DAU 6215, and DAU 6236;

the carboamides





indols, preferably 5-methoxytryptamine, 2-methyl-serotonine, and 5-hydroxy-N,N-di-methyltryptamine;

compounds quaternized on the nitrogen in the side chain:

benzokinolinones



5-carboxamidotryptamine (5-CT), with the structural formula:



3-Me-8-OH-DPAT, 8-OH-DPAT (8-hydroxy-2-dipropyl-aminotetralin), RS 23597-190, RS 67532, RU 28253, SB 204070, Bufotenine, 5-MeO-N,N,DMT, GR 113,808, α-methyl-5-HT, arylcarbamate derivatives of 1-piperidine-ethanol, arylcarbamate derivatives of 1-piperidineethanol, 4-amino-5-chloro-2-methoxybenzoic acid esters, 4-amino-5-chloro-2-methoxy-N-((2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl)benzamide, thiophene carboxamide derivatives 3 (a-j), 5.azabicyclo(x.y.z) derivatives, 2-piperazinylbenzoxazole derivatives, 2-piperazinylbenzothiazole derivatives (e.g. VB20B7), Sandoz compound 1b, clebopride, 2-piperidinmethylethers of benzimidazole, zelmac,



, particularly



2-piperidinmethylethers
of bensimidazol



oxadiazalon based
substance



, particularly



kinolines



, particularly







Q





, particularly



benzopyranes





and derivatives and pharmaceutically acceptable salts thereof.

Claim 2 (Previously Presented): Use according to claim 1, wherein said compound is VB20B7, RS67333, BIMU 1, BIMU 8, 5-methoxytryptamine, Zacopride, RS56532, Mosapride, BRL 24924, or SC 53116.

Claim 3 (Previously Presented): Use according to any one of the previous claims, wherein said disorder involving bronchocontraction is asthma and disorders related thereto.

Claim 4 (Previously Presented): A method for treatment of disorders involving bronchocontraction, wherein said method comprises administering to a human or animal patient suffering from asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, a therapeutically effective amount of a compound according to any one of claims 1 and 2.

Claim 5 (Previously Presented): Use of one or more compounds having antagonist activity to a 5-HT_3 receptor, and derivatives and pharmaceutically acceptable salts thereof having antagonist activity to the 5-HT_3 receptor in the manufacture of a medicament for therapeutic or prophylactic treatment of disorders involving human bronchocontraction, chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, wherein said compounds have the capacity of reducing pathological bronchocontraction by at least 30%, preferably at least 60%, and most preferably at least 90%, and wherein said compound is chosen from the group comprising 5-HT_3 receptor antagonists



benzazepines, preferably mirtazapine



benztiazephines, preferably diltiazem



and fentiazines



preferably perphenazine, stemetil;

compounds also having 5-HT_4 receptor agonist activity, preferably benzamides



(cisapride, zacopride, mosapride, pancropride, BRL 24924, BMY 33462)

and



WAY 100289

2,3-dihydro-benzofuran-7-carboxamides



(preferably zatosetron=LY 277359, ADR 851);

1,4-bensoxazin-8-carboxamides



preferably azasetron (=Y25130);

benzimidazolones



preferably itasetron (=DAU 6215);

indazol-3-carboxamides



preferably N 3389, LY 278584, DAT 582;

wherein the latter group reminds most of the specific 5-HT_3 antagonists, which contains the group



in different forms, such as



ondansetron



alosetron



cilansetron

substances the structure of which has been inverted and the carbonyl group has been placed on the indoline nitrogen



FK 1052

also being an antagonist against both 5-HT_3 and 5-HT_4 receptors,



BRL 46470 A

bisindoles



YM 114

isoquinoline-1-ones



palonosetron (=RS 25259-197)



RS 42358-197

and the quinoline-3-carboxamides



WAY-SEC 579



Mirisetron (=WAY 100579),

quinoline-4-carboxylates



preferably KF 17643



preferably KF 18259;

benzimidazolones



preferably itasetron (DAU6215),

and the naphtimides



RS 56532

preferably RS 56532;

MDL 72222, which also is a specific 5-HT_3 antagonist;



; and



GK 128



Talipexole



iodophenpropit



thioperamide, and



2-piperidin- and 2-piperazin-benzimidazoles; and also

(R)-zacopride, 2-methyl-5HT, 3-(4-allylpiperazin-1-yl)-2-quinoxalinecarbonitrile, 4-Ph-N-Me-quipazine, 5-((dimethylamino)methyl)-3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadizole, 5,7-DHT, 5-[(dimethylamino)methyl]-3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadizole, ADR-882, Amitriptyline, Anpirtoline, AS-5370, Batanopride, BIMU 1, BRL 24682, BRL 43694, BRL 46470 (=Ricasetron), BRL 47204, Bufotenine, CF 109203 (=BIM), Cizapride, Clozapine, CP-93318, Cyameazine, Cyproheptadine, Dolasetron mesilat (=MDL 73147 EF), Fluphenazone, Galdansetron, GR 38032 F, GR 67330, Granisetron (=Kytril=BRL 43694), GR-H, GYKI-48903, ICS 205-930, Indalpine, KAE-393/YM-114, KB-6922, KB-6933, KB-R 6933, KF-20170, Lerisetron, Lurosetron, LY 258-458, LY 278-989, LY-211-000, McNeil-A-343, MCPP, MDL 72699, Mepyramine, Metergoline, Mianserin, MK 212, N-3256, NAN-190, N-metylquipazin, 3-(1-piperazinyl)-2-quinoxalinecarbonitrile, ONO-3051, Phenylbiguanide, Pitozifen, Prochlorperazine, QICS 205-930, R(+)zacopride, Renzapride, RG 12915, Ritanserin, RP 62203, RS-056812-198, RS-25259, RU 24969, S(-)Zacopride, S-apomorfin, SC-52491, SC-53116, SDZ 206-792, SDZ 206-830, SDZ 210-204, SDZ 210-205, SDZ 214-322, SDZ 322, SN-307, TFMPP, TMB 8, trifluoperzine, tropanyl-3,5-dimethylbenzoate, 3-tropanyl-indole-3-carboxylate methiodide, VA 21 B 7, Y 2513, SEC 579, BRL 46470 A, Pizotifen, Dolasetron (=MDL 74156), Galanolactone, GR 65 630, Ifenprodil, L-683877, Litoxetine, QX 222, Ramosetron (=YM 060), RS 56812, SDZ 216-525, Trimebutine, GR 65630, Tropisetron, L-683,877, and pharmaceutically acceptable salts thereof with the same or essentially the same relaxation enhancing effect,

and derivatives and pharmaceutically acceptable salts thereof.

Claim 6 (Previously Presented): Use according to claim 5, wherein said compound is Tropanyl 3,5-dimethylbenzoate, MDL 72222, SDZ 216-525, ICI 169369, Zacopride, Tropisetron, Ramosetron, Ondansetron, Granisetron, Azasetron, Dolasetron, or Cilansetron.

Claim 7 (Previously Presented): Use according to any one of claims 5 and 6, wherein said disorder involving bronchocontraction is asthma and disorders related thereto.

Claim 8 (Previously Presented): A method for treatment of disorders involving bronchocontraction, wherein said method comprises administering to a human or animal patient suffering from asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, a therapeutically effective amount of a compound according to any one of claims 5 and 6.

Claim 9 (Previously Presented): Use of a composition comprising a combination of at least one compound with agonist activity to the 5-HT_4 receptor, and at least one compound with antagonist activity to the 5-HT_3 receptor, for the manufacture of a medicament for therapeutic or prophylactic treatment of disorders involving bronchocontraction, chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, preferably asthma and disorders related thereto.

Claim 10 (Previously Presented): Use according to claim 9, wherein said composition has the capacity of reducing pathological bronchocontraction by at least 30%, preferably at least 60%, and most preferably at least 90%, and wherein said combination is chosen from the following groups of

a) 5-HT_4 receptor agonists:

benzamides containing the structural element 4-amino-5-chloro-2-methoxy benzamide based on metoclopra

mide, with the structural formula:



having a basic nitrogen in a side chain from the amide nitrogen, said basic nitrogen often being a part of a sterically locked system, preferably BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML-1035, Mosapride, R076186, Renzapride, RS 67506, Cinitapride, SB 205149, SC-49518, SC-52491, SC-53116, SDZ 216,454, TKS 159, Y-34959, YM-09151, YM-47813, and Zacopride;

benzoic acid esters:



preferably ML 10302, RS 57639, and SR 59768;

a 2,3-dihydro-bensofuran-7-carboxamide compound,

preferably ADR 932, Prucalopride (=R 093877), and SK-951;



benzofuranes and benzotiophenes,





the benzodioxan



SB 204070

the benzoic acid antagonist RS 23597 (an ester) transformed to an agonist by conversion to a ketone



e.g. preferably RS 67333 and RS 17017;

naphtalimides, preferably RS 56532;



benzindolones;

compounds in which the amide fuction has been replaced with an oxadiazol ring;



preferably YM-53389;

benzimidazolone-1-carboxamides



preferably BIMU 1, BIMU 8, DAU 6215, and DAU 6236;

the carboamides





indols, preferably 5-methoxytryptamine, 2-methyl-serotonine, and 5-hydroxy-N,N-di-methyltryptamine;

compounds quaternized on the nitrogen in the side chain:

benzokinolinones



5-carboxamidotryptamine (5-CT), with the structural formula:



3-Me-8-OH-DPAT, 8-OH-DPAT (8-hydroxy-2-dipropyl-aminotetralin), RS 23597-190, RS 67532, RU 28253, SB 204070, Bufotenine, 5-MeO-N,N,DMT, GR 113,808, α-methyl-5-HT, arylcarbamate derivatives of 1-piperidine-ethanol, arylcarbamate derivatives of 1-piperidineethanol, 4-amino-5-chloro-2-methoxybenzoic acid esters, 4-amino-5-chloro-2-methoxy-N-((2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl)benzamide, thiophene carboxamide derivatives 3 (a-j), 5.azabicyclo(x.y.z) derivatives, 2-piperazinylbenzoxazole derivatives, 2-piperazinylbenzothiazole derivatives (e.g. VB20B7), Sandoz compound 1b, clebopride, 2-piperidinmethylethers of benzimidazole, zelmac,



, particularly



2-piperidinmethylethers
of bensimidazol



oxadiazalon based
substance



, particularly



kinolines



, particularly







Q





, particularly



benzopyranes





and serotonin (5-HT) and derivatives and pharmaceutically acceptable salts thereof.

b) 5-HT_3 receptor antagonists:



benzazepines, preferably mirtazapine



benztiazephines, preferably diltiazem



and fentiazines



preferably perphenazine, stemetil;

compounds also having 5-HT_4 receptor agonist activity, preferably benzamides



(cisapride, zacopride, mosapride, pancropride, BRL 24924, BMY 33462)

and



WAY 100289

2,3-dihydro-benzofuran-7-carboxamides



(preferably zatosetron=LY 277359, ADR 851);

1,4-bensoxazin-8-carboxamides



preferably azasetron (=Y25130);

benzimidazolones



preferably itasetron (=DAU 6215);

indazol-3-carboxamides



preferably N 3389, LY 278584, DAT 582;

wherein the latter group reminds most of the specific 5-HT_3 antagonists, which contains the group



in different forms, such as



ondansetron



alosetron



cilansetron

substances the structure of which has been inverted and the carbonyl group has been placed on the indoline nitrogen



FK 1052

also being an antagonist against both 5-HT_3 and 5-HT_4 receptors,



BRL 46470 A

bisindoles



YM 114

isoquinoline-1-ones





palonosetron (=RS 25259-197)

RS 42358-197

and the quinoline-3-carboxamides





WAY-SEC 579

Mirisetron (=WAY 100579),

quinoline-4-carboxylates



preferably KF 17643



preferably KF 18259;

benzimidazolones



preferably itasetron (DAU6215),

and the naphtimides



RS 56532

preferably RS 56532;

MDL 72222, which also is a specific 5-HT_3 antagonist;



; and



GK 128



Talipexole



iodophenpropit



thioperamide, and



2-piperidin- and 2-piperazin-benzimidazoles; and also

(R)-zacopride, 2-methyl-5HT, 3-(4-allylpiperazin-1-yl)-2-quinoxalinecarbonitrile, 4-Ph-N-Me-quipazine, 5-((dimethylamino)methyl)-3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadizole, 5,7-DHT, 5-[(dimethylamino)methyl]-3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadizole, ADR-882, Amitriptyline, Anpirtoline, AS-5370, Batanopride, BIMU 1, BRL 24682, BRL 43694, BRL 46470 (=Ricasetron), BRL 47204, Bufotenine, CF 109203 (=BIM), Cizapride, Clozapine, CP-93318, Cyameazine, Cyproheptadine, Dolasetron mesilat (=MDL 73147 EF), Fluphenazone, Galdansetron, GR 38032 F, GR 67330, Granisetron (=Kytril=BRL 43694), GR-H, GYKI-48903, ICS 205-930, Indalpine, KAE-393/YM-114, KB-6922, KB-6933, KB-R 6933, KF-20170, Lerisetron, Lurosetron, LY 258-458, LY 278-989, LY-211-000, McNeil-A-343, MCPP, MDL 72699, Mepyramine, Metergoline, Mianserin, MK 212, N-3256, NAN-190, N-metylquipazin, 3-(1-piperazinyl)-2-quinoxalinecarbonitrile, ONO-3051, Phenylbiguanide,

Pitozifen, Prochlorperazine, QICS 205-930, R(+)zacopride, Renzapride, RG 12915, Ritanserin, RP 62203, RS-056812-198, RS-25259, RU 24969, S(-)Zacopride, S-apomorfin, SC-52491, SC-53116, SDZ 206-792, SDZ 206-830, SDZ 210-204, SDZ 210-205, SDZ 214-322, SDZ 322, SN-307, TFMPP, TMB 8, trifluoperzine, tropanyl-3,5-dimethylbenzoate, 3-tropanyl-indole-3-carboxylate methiodide, VA 21 B 7, Y 2513, SEC 579, BRL 46470 A, Pizotifen, Dolasetron (=MDL 74156), Galanolactone, GR 65 630, Ifenprodil, L-683877, Litoxetine, QX 222, Ramosetron (=YM 060), RS 56812, SDZ 216-525, Trimebutine, GR 65630, Tropisetron, L-683,877, and pharmaceutically acceptable salts thereof with the same or essentially the same relaxation enhancing effect, and derivatives and pharmaceutically acceptable salts thereof.

Claim 11 (Previously Presented): Use according to claim 10, wherein the composition comprises the following combinations of a 5-HT_4 receptor agonist and a 5-HT_3 receptor antagonist: VB20B7 and Tropanyl 3,5-dimethylbenzoate, VB20B7 and MDL 72222, RS67333 and Tropanyl 3,5-dimethylbenzoate, RS76333 and MDL 72222, VB20B7 and ICI 169369, RS67333 and ICI 169369, Zacopride and Tropanyl 3,5-dimethylbenzoate, Zacopride and MDL 72222, RS56532 and Tropanyl 3,5 dimethylbenzoate, RS56532 and MDL 72222, Itasetron and Tropanyl 3,5-dimethylbenzoate, Itasetron and MDL 72222, VB20B7 and SDZ 216-525, and RS67333 and SDZ 216-525.

Claim 12 (Previously Presented): A method for treatment of disorders involving bronchocontraction chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, wherein said method comprises administering to a human or animal patient a therapeutically effective amount of a composition according to any one of claims 10 and 11.

Claim 13 (Previously Presented): A method for treatment of disorders involving bronchocontraction chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic

wherein said method comprises administering to a human or animal patient a therapeutically effective amount of a 5-HT_4 receptor agonist according to any one of claims 1 and 2 and a 5-HT_3 receptor antagonist according to any one of claims 5 and 6, either simultaneously or sequentially.

14-17 (canceled)

18. (new) Method of treating disorders involving human bronchocontraction, chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease comprising:

administering one or more compounds having agonist activity to a 5-HT_4 receptor,

wherein said one or more compounds have the capacity of reducing pathological bronchocontraction by at least 30%, preferably at least 60%, and most preferably at least 90%.

19. (new) Method of claim 18, wherein said one or more compounds are chosen from the group comprising the following 5-HT_4 receptor agonists: benzmides containing the structural element 4-amino-5-chloro-2-methoxy benzamide, optionally having a basic nitrogen in a side chain from the amide nitrogen, said basic nitrogen often being a part of a sterically locked system, preferably BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML-1035, Mosapride, RO76186, Renzapride, RS 67506, Cinitapride, SB 205149, SC-49518, SC-52491, SC-53116, SDZ 216,454, TKS 159, Y-34959, YM-09151, YM-47813, and Zacopride;

benzoic acid esters:

preferably ML 10302, RS 57639, and SR 59768;

a 2, 3-diyhdro-bensofuran-7-carboxamide compound, preferably ADR 932, Prucalopride (=R 093877), and SK-951;

benszofuranes and benzotiophenes,

the benzodioxan



the benzoic acid antagonist RS 23597 (an ester) transformed to an agonist by conversion to a ketone



e.g. RS 67333 and RS 17017.

naphtalimides, preferably RS 56532;



benzindolones;

compounds in which the amide fuction has been replaced with an oxadiazol ring;



preferably YM-53389;

benzimidazolone-1-carboxamides

preferably BIMU 1, BIMU 8, DAU 6215, and DAU 6236;

the carboamides





Indols, preferably 5-methoxytryptamine, 2-methylserotonine, and 5-hydroxy-N,N-dimethyltryptamine;

Compounds quartenized on the nitrogen in the side chain:

bensokinolinones

5-carboxamidotryptamine (5-CT), with the structural formula:



5-HT, 3-Me-8-OH-DPAT, 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin), RS 23597-190, RS 67532, RU 28253, SB 204070, Bufotenine, 5-MeO-N,N,DMT, GR 113,808, α-methyl-5-HT, arylcarbamate derivatives of 1-piperidineethanol, arylcarbamate derivatives of 1-piperidineethanol, 4-amino-5-chloro-2-methoxybenzoic acid esters, 4-amino-5-chloro-2-methoxy-N-((2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl)benzamide, thiophene carboxamide derivatives 3 (a-j), 5.azabicyclo(x.y.z) derivatives, 2-piperazinylbenzoxazole derivatives, 2-piperazinylbenzothiazole derivatives (e.g. VB20B7), Sandoz compound 1b, clebopride, 2-piperidinmethylethers of benzimidazole, zelmac,



, particularly



2-piperidinmethylethers
of bensimidazol



oxadiazalon based
substance



, particularly



kinolines



, particularly







Q





, particularly



bensopyranes





and derivatives and pharmaceutically acceptable salts thereof.

20. (new) Method of claim 18, wherein said one or more compounds is VB20B7, RS67333, BIMU 1, BIMU 8, 5-methoxytryptamine, Zacopride, RS565323, Mosapride, BRL 24924, or SC 53116.

21. (new) Method according to claims 18-20, wherein said disorder involving bronchocontraction is asthma and disorders related thereto.